Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
David König, Jürgen Hench, Stephan Frank, Laura Dima, Ivana Bratić Hench, Heinz Läubli
Abstract
High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.
Topics & Concepts
TemozolomideGliomaMedicineGlioblastomaBrain tumorFusion proteinSurgical resectionOncologyCancer researchInternal medicinePathologyBiologyGeneBiochemistryRecombinant DNAGlioma Diagnosis and TreatmentNeuroblastoma Research and TreatmentsBrain Metastases and Treatment